In addition to the expected improvements in lipid profile , atorvastatin treatment significantly reduced circulating eotaxin-1 ( P < 005 ) , MIP-1 ( P < 005 ) levels and CD14 ( + ) peripheral monocyte CCR5 mRNA expression ( P = 002 ) .
